Proprietary bi-functional ADCs target and inhibit unique Delta receptor on tumor-associated Myeloid Derived Suppressor Cells (MDSCs); increasing tumor’s susceptibility to...
WORCESTER, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical...
Renowned scientist and serial entrepreneur Jeff Karp, Ph.D., brings deep research experience and industry knowledge that will help guide Eterna...
Glen Rock, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx” or the “Company”) is pleased...
Combination Test Also Secures Point-Of-Care Authorization in Australia Lucira COVID-19 & Flu Home Test – The First & Only Combination...
Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpointsVTP-300 is the first antigen-specific immunotherapy shown to induce...
KET01 Phase 2 Clinical Trial with Topline Results Expected Mid-YearMUNICH, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health...
Real-World Evidence Demonstrates the Highest Response and Remission Rates Observed to Date for Deep BURLINGTON, Mass. and JERUSALEM, March 28, 2023...
Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory...
First TIL Therapy BLA Submission to U.S. Food and Drug AdministrationSAN CARLOS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Iovance...
Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER PLUS trial, a phase 3b,...
Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca RatonBOCA RATON, Fla. and VIENNA, Austria, March...
OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage...
Reports significant enhancements to accelerate Tigris patient enrollment including appointment of new Contract Research Organization Management to host Investor Day...
Reprioritized product portfolio to focus on IV-administered, self-amplifying RNA medicinesOn track to submit IND for ONCR-021 in mid-2023Preclinical data featured...
BOSTON, March 24, 2023 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing novel therapeutics to address mechanisms of metastasis,...
-- Enrollment Nearing Completion in Human Acellular Vessel™ (HAV™) Phase 2/3 Trial in Vascular Trauma and Phase 3 Trial in...
TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023Phase 2 proof-of-concept trial of farudodstat...
atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living...
Common Stock Will Begin Trading on a Post-Split Adjusted Basis on March 27, 2023 Press releaseBOSTON, Mass - March 24,...